Similar articles

• [Aztreonam in severe gram-negative infections in hospitalized patients. Clinical experience in Spain. Preliminary data].

  García-Rodríguez JA, Rabinad E. García-Rodríguez JA, et al. Med Clin (Barc). 1987 Apr 4;88(13):538-43. Med Clin (Barc). 1987. PMID: 3586736 Spanish. No abstract available.
• Aztreonam in the treatment of serious gram-negative infections in the elderly.

  Deger F, Douchamps J, Freschi E, Thys JP, Nève P, Herchuelz A. Deger F, et al. Int J Clin Pharmacol Ther Toxicol. 1988 Jan;26(1):22-6. Int J Clin Pharmacol Ther Toxicol. 1988. PMID: 3403089
• Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.

  LeFrock JL, Smith BR, Chandrasekar P, Rolston KV, Molavi A, Kannangara W. LeFrock JL, et al. Arch Intern Med. 1987 Feb;147(2):325-8. Arch Intern Med. 1987. PMID: 3813751
• Role of aztreonam in lower respiratory tract infections.

  Cook JL. Cook JL. Urology. 1988 Jun;31(6 Suppl):33-6. Urology. 1988. PMID: 3287748 Review.
• Aztreonam: the first monobactam antibiotic.

  Stutman HR. Stutman HR. Pediatr Infect Dis J. 1987 Jun;6(6):550-5. Pediatr Infect Dis J. 1987. PMID: 3302907 Review. No abstract available.